Vimta Labs Limited (IN:VIMTALABS)
:VIMTALABS
Want to see IN:VIMTALABS full AI Analyst Report?
VIMTALABS Stock Chart & Stats
₹609.25
-₹18.70(-1.83%)
At close: 4:00 PM EST
₹609.25
-₹18.70(-1.83%)
Day’s Range― - ―
52-Week Range₹377.30 - ₹902.85
Previous CloseN/A
Volume71.13K
Average Volume (3M)22.50K
Market Cap
₹23.27B
Enterprise Value₹20.36B
Total Cash (Recent Filing)₹564.64M
Total Debt (Recent Filing)₹67.97M
Price to Earnings (P/E)30.0
Beta1.07
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.16%
Share Statistics
EPS (TTM)17.65
Shares Outstanding44,669,353
10 Day Avg. Volume11,086
30 Day Avg. Volume22,501
Financial Highlights & Ratios
PEG Ratio1.47
Price to Book (P/B)3.71
Price to Sales (P/S)4.16
P/FCF Ratio34.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)20.1
Revenue Forecast (FY)₹4.71B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and rising equity materially reduce financial risk and preserve strategic optionality. This balance-sheet strength supports capex for lab capacity, tolerates cyclic demand swings in outsourced testing, and lowers refinancing pressure over the medium term.
High And Durable MarginsConsistently mid-to-high teen net margins and mid-30% EBITDA indicate structural cost advantages and pricing power in regulated testing and CRO services. These margins provide internal funding for reinvestment and buffer against periodic margin pressure, aiding long-term profitability.
Fee-based Outsourced Services ModelA diversified fee-for-service model across analytical testing, clinical research and support creates recurring project revenue and long-term client relationships. Structural outsourcing trends in pharma/biotech and regulatory complexity favor specialist labs, supporting durable demand.
Bears Say
Margin VolatilityMaterial swings in gross and operating margins suggest exposure to mix shifts, pricing pressure or cost variability. Persistent volatility reduces earnings predictability, complicates capital allocation and raises execution risk for sustaining long-term margin targets.
Uneven Cash ConversionWhile operating cash flow rebounded recently, inconsistent free cash flow and prior negative FCF indicate working-capital swings and variable conversion. This can constrain organic funding for expansion or acquisitions and may force external financing in weaker periods.
Stagnant Return ExpansionROE remaining mid-teens despite rising equity suggests limited improvement in capital efficiency. Without expanding returns or higher asset turnover, additional equity growth risks diluting rate of return, limiting shareholder value uplift as the company scales.
Vimta Labs Limited News
VIMTALABS FAQ
What was Vimta Labs Limited’s price range in the past 12 months?
Vimta Labs Limited lowest stock price was ₹377.30 and its highest was ₹902.85 in the past 12 months.
What is Vimta Labs Limited’s market cap?
Vimta Labs Limited’s market cap is ₹23.27B.
When is Vimta Labs Limited’s upcoming earnings report date?
Vimta Labs Limited’s upcoming earnings report date is Aug 14, 2026 which is in 63 days.
How were Vimta Labs Limited’s earnings last quarter?
Vimta Labs Limited released its earnings results on May 06, 2026. The company reported ₹4.726 earnings per share for the quarter, beating the consensus estimate of N/A by ₹4.726.
Is Vimta Labs Limited overvalued?
According to Wall Street analysts Vimta Labs Limited’s price is currently Overvalued.
Does Vimta Labs Limited pay dividends?
Vimta Labs Limited pays a Annually dividend of ₹2 which represents an annual dividend yield of 0.16%. See more information on Vimta Labs Limited dividends here
What is Vimta Labs Limited’s EPS estimate?
Vimta Labs Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vimta Labs Limited have?
Vimta Labs Limited has 44,669,353 shares outstanding.
What happened to Vimta Labs Limited’s price movement after its last earnings report?
Vimta Labs Limited reported an EPS of ₹4.726 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.338%.
Which hedge fund is a major shareholder of Vimta Labs Limited?
Currently, no hedge funds are holding shares in IN:VIMTALABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vimta Labs Limited
Vimta Labs Limited provides specialized contract research and analytical testing services, operating both within India and internationally. Their extensive offerings encompass general laboratory analyses, comprehensive food and water quality testing, support for preclinical and clinical research, detailed structural and functional assessments of biological molecules, environmental impact studies, and clinical diagnostic reference laboratory capabilities. The company serves a wide array of industries, including pharmaceuticals, biopharmaceuticals, food production, consumer goods, electronics, electrical equipment, agrochemicals, healthcare, medical devices, and many more. Established in 1984, Vimta Labs Limited is headquartered in Hyderabad, India.
Technical Analysis
Krsnaa Diagnostics Limited
―
Dr. Lal PathLabs Limited
―
Metropolis Healthcare Ltd.
―
Thyrocare Technologies Ltd
―
Vijaya Diagnostic Centre Ltd.
―